Infliximab or Vedolizumab in Treating Immune Checkpoint Inhibitor-Related Colitis in Patients With Genitourinary Cancer or Melanoma

Conditions:   Colitis;   Lung Non-Small Cell Carcinoma;   Malignant Genitourinary System Neoplasm;   Malignant Solid Neoplasm;   Melanoma Interventions:   Biological: Infliximab;   Biological: Vedolizumab Sponsors:   M.D. Anderson Cancer Center;   National Cancer Institute (NCI) Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials